SUMMARY:
In vivo transfer of AAV2-hSaCas9-gRNAedit to peripheral nerves could be a potential therapeutic modality for CMT1A patient.
TITLE:
AAV-mediated editing of PMP22 rescues Charcot-Marie-Tooth disease type 1A features in patient-derived iPS Schwann cells
DESCRIPTION:
CONCLUSIONS: In vivo transfer of AAV2-hSaCas9-gRNAedit to peripheral nerves could be a potential therapeutic modality for CMT1A patient after careful examinations of toxicity including off-target mutations.
CONTENT:
Commun Med (Lond). 2023 Nov 28;3(1):170. doi: 10.1038/s43856-023-00400-y.
ABSTRACT
BACKGROUND: Charcot-Marie-Tooth disease type 1A (CMT1A) is one of the most common hereditary peripheral neuropathies caused by duplication of 1.5 Mb genome region including PMP22 gene. We aimed to correct the duplication in human CMT1A patient-derived iPS cells (CMT1A-iPSCs) by genome editing and intended to analyze the effect on Schwann cells differentiated from CMT1A-iPSCs.
METHODS: We designed multiple gRNAs targeting a unique sequence present at two sites that sandwich only a single copy of duplicated peripheral myelin protein 22 (PMP22) genes, and selected one of them (gRNA3) from screening their efficiencies by T7E1 mismatch detection assay. AAV2-hSaCas9-gRNAedit was generated by subcloning gRNA3 into pX601-AAV-CMV plasmid, and the genome editing AAV vector was infected to CMT1A-iPSCs or CMT1A-iPSC-derived Schwann cell precursors. The effect of the genome editing AAV vector on myelination was evaluated by co-immunostaining of myelin basic protein (MBP), a marker of mature myelin, and microtubule-associated protein 2(MAP2), a marker of neurites or by electron microscopy.
RESULTS: Here we show that infection of CMT1A-iPS cells (iPSCs) with AAV2-hSaCas9-gRNAedit expressing both hSaCas9 and gRNA targeting the tandem repeat sequence decreased PMP22 gene duplication by 20-40%. Infection of CMT1A-iPSC-derived Schwann cell precursors with AAV2-hSaCas9-gRNAedit normalized PMP22 mRNA and PMP22 protein expression levels, and also ameliorated increased apoptosis and impaired myelination in CMT1A-iPSC-derived Schwann cells.
CONCLUSIONS: In vivo transfer of AAV2-hSaCas9-gRNAedit to peripheral nerves could be a potential therapeutic modality for CMT1A patient after careful examinations of toxicity including off-target mutations.
PMID:38017287 | DOI:10.1038/s43856-023-00400-y
SOURCE:
Communications medicine
TAGS:
AAV2hSaCas9gRNAedit
CATEGORY:
Research
SUBCATEGORY:
n/a
DATE – PUBLISHED:
2023-11-28T11:15:02Z
DATE – DOI: 2023-11-28T11:15:02Z
DATE – PUBMED: 2023 Nov 28
DATE OUTPUT MATCHED: True
DATE – ADDED:
Tue, 28 Nov 2023 06:00:00 -0500
DATE – RETRIEVED:
11/29/23 12:38AM
2023-11-29T00:38:12-05:00
FEATURED IMAGE:
Media Uploaded (image/jpeg)
IDENTIFIER:
pmid:38017287,doi:10.1038/s43856-023-00400-y
PUBMED ID:
pubmed:38017287
DOI:
10.1038/s43856-023-00400-y
LINK – PUBMED:
https://pubmed.ncbi.nlm.nih.gov/38017287/
LINK – DOI:
https://doi.org/10.1038/s43856-023-00400-y
LINK – PUBLISHER:
https://www.nature.com/articles/s43856-023-00400-y
REFERENCES:
CMT Treatment Report, Urgent Research, 2023-11-29T00:38:12-05:00, https://www.cmttreatmentreport.com.
